FILIBUVIR

FILIBUVIR

Biochem/physiol Actions

Filibuvir is an orally available, potent and selective inhibitor of the hepatitis C virus (HCV) nonstructural 5B (NS5B) RNA-dependent RNA polymerase that exhibits potent antiviral activity against subgenomic HCV replicons in cell culture assays. Also, Filibuvir potently inhibits viral replication in infected patients. Filibuvir interacts with the thumb site II of the viral polymerase.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Immunology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3573553 FILIBUVIR white to beige 100 SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear powder ≥98% (HPLC)
£435.96 (exc VAT) per 25MG
-
+
3573554 FILIBUVIR white to beige 100 SIGMA-ALDRICH room temp DMSO: 10 mg/mL, clear powder ≥98% (HPLC)
£136.50 (exc VAT) per 5MG
-
+